Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

FDA Approved Drugs: Changes to Approved Drugs

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...

Drug Regulation

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...

Renal Drug Excretion: Overview

Renal Drug Excretion: Overview

As primary excretory organs, the kidneys maintain homeostasis by removing waste substances from the bloodstream. They comprise over a million units called nephrons, which serve as the kidney's functional units.
A nephron consists of two primary structures: the renal corpuscle and the renal tubule. The renal corpuscle contains the glomerulus, a network of capillaries where the first step of renal excretion, glomerular filtration, occurs. Blood pressure forces water, ions, and small molecules out...

Antiprotozoal Agents

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...

Renal Drug Clearance: Overview

Renal Drug Clearance: Overview

Renal clearance is a crucial parameter in pharmacokinetics that quantifies the rate at which the kidneys excrete a drug. It represents a constant fraction of the central volume of distribution containing the drug that the kidney eliminates per unit of time.
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Preparedness against mobility disruption by floods.

The Science of the total environment·2019

Same author

Synthesis and in vitro activity of D- and L-enantiomers of 5-(trifluoromethyl)uracil nucleoside derivatives.

Nucleosides, nucleotides & nucleic acids·2001

Same author

Immobilized penicillin G acylase as reactor and chiral selector in liquid chromatography.

Journal of chromatography. A·2001

Same author

5-(Trifluoromethyl)-beta-l-2'-deoxyuridine, the L-enantiomer of trifluorothymidine: stereospecific synthesis and antiherpetic evaluations.

Bioorganic & medicinal chemistry·2001

Same author

Potentiation of inhibition of wild-type and mutant human immunodeficiency virus type 1 reverse transcriptases by combinations of nonnucleoside inhibitors and d- and L-(beta)-dideoxynucleoside triphosphate analogs.

Antimicrobial agents and chemotherapy·2001

Same author

3H-[1,2]Dithiolo[3,4-b]pyridine-3-thione and its derivatives synthesis and antimicrobial activity.

Farmaco (Societa chimica italiana : 1989)·2001

Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010

Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010

Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010

Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010

Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010

Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010

See all related articles

Search research articles

Related Experiment Video

Updated: Jul 5, 2026

Urethral Stricture Induction Followed by Buccal Mucosa Graft Urethroplasty in a Rat Model

Urethral Stricture Induction Followed by Buccal Mucosa Graft Urethroplasty in a Rat Model

Published on: April 28, 2023

Rifalazil(Kaneka corp).

Idrugs : the Investigational Drugs Journal

|May 10, 2008

Summary

This summary is machine-generated.

Rifalazil, a novel rifamycin derivative, shows promise in treating tuberculosis and MAC infections. Early trials indicate potent efficacy and a favorable safety profile compared to rifampin.

More Related Videos

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

Related Experiment Videos

Last Updated: Jul 5, 2026

Urethral Stricture Induction Followed by Buccal Mucosa Graft Urethroplasty in a Rat Model

Urethral Stricture Induction Followed by Buccal Mucosa Graft Urethroplasty in a Rat Model

Published on: April 28, 2023

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

Area of Science:

Pharmacology and Infectious Diseases
Drug Development
Microbiology

Background:

Rifalazil is a rifamycin derivative developed for Mycobacterium tuberculosis (TB) and Mycobacterium avium complex (MAC) infections.
It is undergoing Phase II clinical trials for TB and AIDS-associated MAC infections.
PathoGenesis holds exclusive rights for its development and marketing in the US and Mexico.

Purpose of the Study:

To evaluate the efficacy and safety of rifalazil in treating TB and MAC infections.
To compare rifalazil in combination regimens with standard treatments.
To assess the early bactericidal activity of rifalazil.

Main Methods:

Phase II clinical trial in Brazil with 60 pulmonary TB patients.
Four dosing regimens comparing rifalazil plus isoniazid against isoniazid alone or with rifampin over 14 days.
Phase I trials in the US for both indications completed in 1996.

Main Results:

Preclinical studies show rifalazil is 30-fold more potent than rifampin against M tuberculosis and MAC.
Phase I trials demonstrated a favorable safety profile at low doses, with no side-effects seen with rifampin.
Rifalazil exhibits a longer half-life (24h) compared to rifampin (2-3h).

Conclusions:

Rifalazil demonstrates significant preclinical potency and a promising safety profile for TB and MAC treatment.
Its longer half-life and improved efficacy suggest potential as a valuable therapeutic agent.
Ongoing clinical trials will further elucidate its clinical utility.